Galmed Pharmaceuticals Lt... (GLMD)

NasdaqCM: GLMD · Real-Time Price · USD

4.32

-0.24 (-5.26%)

At close: Aug 21, 2026, 9:56 AM

The price, the headline numbers and the latest news, in one place.

-5.26% (1D)

Bid	3.32
Market Cap	4.75M
Revenue (ttm)	n/a
Net Income (ttm)	-11.12M
	0.68
	-16.48
	n/a
	-4.43
P/B (ttm)	2.16
P/S (ttm)	n/a
Earnings Date	n/a

Ask	5.44
Volume	2,530
Avg. Volume (20D)	101,882
Open	4.54
Previous Close	4.56
Day's Range	4.29 - 4.54
52-Week Range	3.29 - 13.20
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About GLMD

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The comp...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 13, 2014

Employees 3

Stock Exchange NasdaqCM

Ticker Symbol GLMD

Website https://galmedpharma.com

Full Company Profile

Financial Performance

In 2025, Galmed Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -10.31M, an increase of 37.14%.

Financial Statements

Earnings Surprise

Galmed Pharmaceuticals has released their quarterly earnings on Jul 8, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.

EPS of -0.29 exceeds estimates by 0.09, with 53.23% YoY growth.

News

1 month ago · InvestorsHub

Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)

Galmed announced the development of a lipid nanoparticle formulation of Aramchol designed to target heart tissue, marking a potential expansion of the drug beyond its existing liver and gastrointestin...

8 months ago · Associated Press Finance

Galmed Pharmaceuticals: Q3 Earnings Snapshot

RAMAT GAN, Israel (AP) — Galmed Pharmaceuticals Ltd. (GLMD) on Wednesday reported a loss of $1.9 million in its third quarter. The Ramat Gan, Israel-based company said it had a loss of 33 cents per sh...

9 months ago · Associated Press Finance

BC-Most Active Stocks

HIVE Digital Technologies Ltd. 30,450,329 3.7899

11 months ago · Associated Press Finance

Galmed Pharmaceuticals: Q2 Earnings Snapshot

RAMAT GAN, Israel (AP) — Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported net income of $2.5 million in its second quarter. On a per-share basis, the Ramat Gan, Israel-based company said it had...